RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients\n\nWOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stag
https://www.reddit.com/r/darksideofwo/comments/18a0930/woodcut_and_chop/
https://youtube.com/live/b9bFq6VeraI?feature=share